Skip to main content
SpringerLink
Log in

Understanding the differences among inotropes

  • Understanding the Disease
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mebazaa A, Parissis J, Porcher R et al (2011) Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37:290–301. doi:10.1007/s00134-010-2073-4

    Article  PubMed  Google Scholar 

  2. Cecconi M, De Backer D, Antonelli M et al (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 40:1795–1815. doi:10.1007/s00134-014-3525-z

    Article  PubMed Central  PubMed  Google Scholar 

  3. Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997–1003. doi:10.1016/S0735-1097(02)02968-6

    Article  CAS  PubMed  Google Scholar 

  4. Papp Z, Édes I, Fruhwald S et al (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159:82–87. doi:10.1016/j.ijcard.2011.07.022

    Article  PubMed  Google Scholar 

  5. Hasenfuss G, Teerlink JR (2011) Cardiac inotropes: current agents and future directions. Eur Heart J 32:1838–1845. doi:10.1093/eurheartj/ehr026

    Article  CAS  PubMed  Google Scholar 

  6. Cleland JGF, Teerlink JR, Senior R et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378:676–683. doi:10.1016/S0140-6736(11)61126-4

    Article  CAS  PubMed  Google Scholar 

  7. Mebazaa A, Nieminen MS, Filippatos GS et al (2009) Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 11:304–311. doi:10.1093/eurjhf/hfn045

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Mebazaa A, Pitsis AA, Rudiger A et al (2010) Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 14:201. doi:10.1186/cc8153

    Article  PubMed Central  PubMed  Google Scholar 

  9. Koster G, Wetterslev J, Gluud C et al (2014) Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. doi:10.1007/s00134-014-3604-1

    PubMed  Google Scholar 

  10. Pirracchio R, Parenica J, Resche Rigon M et al (2013) The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One 8:e71659. doi:10.1371/journal.pone.0071659

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Rudiger A, Singer M (2013) The heart in sepsis: from basic mechanisms to clinical management. Curr Vasc Pharmacol 11:187–195

    CAS  PubMed  Google Scholar 

  12. Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684. doi:10.1016/S0140-6736(07)61344-0

    Article  CAS  PubMed  Google Scholar 

  13. Hernandez G, Bruhn A, Luengo C et al (2013) Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med 39:1435–1443. doi:10.1007/s00134-013-2982-0

    Article  CAS  PubMed  Google Scholar 

  14. Morelli A, De Castro S, Teboul J-L et al (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644. doi:10.1007/s00134-005-2619-z

    Article  PubMed  Google Scholar 

  15. Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883–1891. doi:10.1001/jama.297.17.1883

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

MA has no conflict of interest to declare. AM is member of advisory boards for Bayer, Cardiorentis and The Medicines Company and received lecture fees from Alere, Edwards, Orion, Novartis, Vifor and Thermofisher.

Author information

Authors and Affiliations

  1. Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland

    Mattia Arrigo

  2. PRES Sorbonne Paris Cité, Université Paris Diderot, Paris, France

    Alexandre Mebazaa

  3. Department of Anesthesiology and Critical Care Medicine, APHP, Saint Louis Lariboisière University Hospitals, 2, Rue Ambroise Paré, 75475, Paris Cedex 10, France

    Alexandre Mebazaa

  4. U942 INSERM, Paris, France

    Mattia Arrigo & Alexandre Mebazaa

Authors
  1. Mattia Arrigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandre Mebazaa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandre Mebazaa.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arrigo, M., Mebazaa, A. Understanding the differences among inotropes. Intensive Care Med 41, 912–915 (2015). https://doi.org/10.1007/s00134-015-3659-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-015-3659-7

Keywords

Search

Navigation